Straus Sabrina, Farah Marc, Pillai Kathryn, Siracuse Jeffrey J, Alsaigh Tom, Malas Mahmoud
Division of Vascular & Endovascular Surgery, Department of Surgery, Center for Learning and Excellence in Vascular and Endovascular Research (CLEVER), UC San Diego (UCSD), San Diego, CA.
Division of Vascular & Endovascular Surgery, Department of Surgery, Center for Learning and Excellence in Vascular and Endovascular Research (CLEVER), UC San Diego (UCSD), San Diego, CA; Division of Vascular Surgery, Georgetown University School of Medicine, Washington, DC.
J Vasc Surg. 2025 Mar;81(3):606-612. doi: 10.1016/j.jvs.2024.11.030. Epub 2024 Nov 29.
Hypertension (HTN) has been well-documented as a strong predictive factor for worse outcomes in patients undergoing various cardiovascular procedures. However, limited research has investigated the effect of controlled vs uncontrolled HTN (uHTN) preoperatively in patients undergoing elective endovascular aneurysm repair (EVAR). Using a national database, we aimed to determine whether there are significant differences in outcomes between these two groups to improve quality of care and preoperative management.
We studied patients undergoing EVAR in the Vascular Quality Initiative from 2020 to 2023. Patients were categorized into three groups: no history of HTN, controlled HTN (cHTN), and uHTN. The definition of HTN in this study was based on documented history of HTN or recorded blood pressures on three or more occasions before the procedure. Patients with cHTN included patients treated with medication and having a blood pressure of <130/80. Patients with uHTN had a blood pressure of >130/80. Our primary outcome was perioperative death. Secondary outcomes included myocardial infarction and other cardiac complications, pulmonary complications, bowel and leg ischemia, acute kidney injury, and prolonged intensive care unit (ICU) length of stay (LOS) (>1 day). We used logistic regression models for a multivariate analysis, controlling for confounding variables.
A total of 11,938 patients without HTN (34.6%) , 17,926 patients with cHTN (52.0%) , and 4598 patients with uHTN (13.3%) were analyzed. Patients with cHTN and uHTN had higher rates of comorbidities, including prior coronary artery disease, diabetes, and congestive heart failure and were more likely receiving aspirin and statin compared with patients with no HTN. In the multivariate analysis, patients with uHTN had higher risk of perioperative death (adjusted odd ratio [aOR], 2.64; 95% confidence interval [CI], 1.44-4.88; P = .002), and prolonged ICU LOS (aOR, 1.52; 95% CI, 1.25-1.83; P < .001) compared with patients without HTN. Patients with patients with cHTN had a significantly lower rate of perioperative death (aOR, 0.60; 95% CI, 0.38-0.96; P = .029), cardiac complications (aOR, 0.60; 95% CI, 0.38-0.99; P = .036), and prolonged ICU LOS (aOR, 0.55; 95% CI, 0.46-0.66; P < .001) compared with patients with uHTN. Notably, there was no significant difference in perioperative mortality or in-hospital complications between patients with cHTN and those with no history of HTN.
Patients with uHTN are more likely to experience worse outcomes-including perioperative death, cardiac complications, and prolonged ICU stay-compared with patients with no HTN and those with cHTN. Patients with cHTN had similar outcomes to patients with no HTN. These results highlight the importance of regulating blood pressures before undergoing elective EVAR to improve patients' overall outcomes. Further studies may add more insight into the optimal duration of blood pressure control before EVAR.
高血压(HTN)已被充分证明是接受各种心血管手术患者预后较差的一个强有力的预测因素。然而,关于择期血管内动脉瘤修复术(EVAR)患者术前血压控制与未控制(uHTN)的影响的研究有限。我们利用一个全国性数据库,旨在确定这两组患者在预后方面是否存在显著差异,以提高医疗质量和术前管理水平。
我们研究了2020年至2023年血管质量倡议中接受EVAR的患者。患者被分为三组:无高血压病史、血压控制良好的高血压(cHTN)和未控制的高血压(uHTN)。本研究中高血压的定义基于高血压病史记录或术前三次或更多次记录的血压。cHTN患者包括接受药物治疗且血压<130/80的患者。uHTN患者的血压>130/80。我们的主要结局是围手术期死亡。次要结局包括心肌梗死和其他心脏并发症、肺部并发症、肠道和腿部缺血、急性肾损伤以及重症监护病房(ICU)住院时间延长(>1天)。我们使用逻辑回归模型进行多变量分析,控制混杂变量。
共分析了11938例无高血压患者(34.6%)、17926例cHTN患者(52.0%)和4598例uHTN患者(13.3%)。与无高血压患者相比,cHTN和uHTN患者的合并症发生率更高,包括既往冠状动脉疾病、糖尿病和充血性心力衰竭,且更可能接受阿司匹林和他汀类药物治疗。在多变量分析中,与无高血压患者相比,uHTN患者围手术期死亡风险更高(调整后的比值比[aOR],2.64;95%置信区间[CI],1.44 - 4.88;P = .002),ICU住院时间延长(aOR,1.52;95% CI,1.25 - 1.83;P < .001)。与uHTN患者相比,cHTN患者围手术期死亡率(aOR,0.60;95% CI,0.38 - 0.96;P = .029)、心脏并发症(aOR,0.60;95% CI,0.38 - 0.99;P = .036)和ICU住院时间延长(aOR,0.55;95% CI,0.46 - 0.66;P < .001)的发生率显著更低。值得注意的是,cHTN患者与无高血压病史患者在围手术期死亡率或院内并发症方面无显著差异。
与无高血压患者和cHTN患者相比,uHTN患者更有可能出现较差的结局,包括围手术期死亡、心脏并发症和ICU住院时间延长。cHTN患者与无高血压患者的结局相似。这些结果凸显了在接受择期EVAR术前控制血压以改善患者总体结局的重要性。进一步的研究可能会更深入地了解EVAR术前血压控制的最佳时长。